Premium
Efficacy and safety of liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue, in L atino/ H ispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials
Author(s) -
Davidson J. A.,
Ørsted D. D.,
Campos C.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12653
Subject(s) - liraglutide , medicine , type 2 diabetes , placebo , sitagliptin , post hoc analysis , endocrinology , diabetes mellitus , lira , exenatide , glucagon like peptide 1 receptor , weight loss , agonist , pharmacology , gastroenterology , receptor , obesity , alternative medicine , pathology , exchange rate , economics , macroeconomics
The aim of the present analysis was to evaluate the efficacy of the glucagon‐like peptide‐1 receptor agonist liraglutide in L atino/ H ispanic individuals with type 2 diabetes, in addition to comparing its treatment effects with those observed in non‐ L atino/ H ispanic individuals. Analyses were performed on patient‐level data from a subset of individuals self‐defined as L atino/ H ispanic from four phase III studies, the LEAD ‐3, LEAD ‐4, LEAD ‐6 and 1860‐ LIRA‐DPP ‐4 trials. Endpoints included change in glycated haemoglobin ( HbA1c ) and body weight from baseline. In L atino/ H ispanic patients (n = 505; 323 treated with liraglutide) after 26 weeks, mean HbA1c reductions were significantly greater with both liraglutide 1.2 and 1.8 mg versus comparator or placebo in the LEAD ‐3 and LEAD ‐4 studies, and with 1.8 mg liraglutide in the 1860‐ LIRA‐DPP ‐4 trial. In LEAD ‐3 both doses led to significant differences in body weight change among L atino/ H ispanic patients versus the comparator. With 1.8 mg liraglutide, difference in weight change was significant only in the 1860‐ LIRA‐DPP ‐4 trial versus sitagliptin. For both endpoints L atino/ H ispanic and non‐ L atino/ H ispanic patients responded to liraglutide similarly. In summary, liraglutide is efficacious for treatment of type 2 diabetes in L atino/ H ispanic patients, with a similar efficacy to that seen in non‐ L atino/ H ispanic patients.